RE: Promedior Announces Completion of Acquisition by Roche23 Apr 2020 23:29
To become a Unicorn (£1B valuation, around 216pps) NFX only need (for NPX002 alone):
@10% royalies
£70,000 per patient year drug cost
~20% overhead
ONLY around 9,000 patients
The US has 160,000 IPF sufferers, China and EU, multiple of that ??